clinical trial · NCT03375242
Safety and Efficacy of Xalkori ROS1
Pfizer·—·active not recruiting·n = 97
Non-small Cell Lung Cancercrizotinib
brief summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
started
Oct 25, 2017
primary completion
Nov 6, 2026
completion
Nov 6, 2026
last updated
Mar 30, 2026
official title
XALKORI ROS1+NSCLC DRUG USE INVESTIGATION
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol